Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3365 participants.
Also called NCT02064439
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 3,365 participants
- Registry
-
NCT02064439 -
2013-000619-26
-
- Other papers using this trial's data
- Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT02064439. Randomized; quadruple masking; primary purpose prevention. Start 2014-03-05 (actual); primary completion 2016-09-22 (actual). Results posted on 2017-12-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
- Acronym
- EinsteinChoice
- Condition
- Pulmonary Embolism
- Condition
- Thromboembolism
- Condition
- Thrombosis
- Condition
- Venous Thrombosis
- Condition
- Venous Thromboembolism
- Intervention (Drug)
- BAY 59-7939
- Intervention (Drug)
- BAY 59-7939
- Intervention (Drug)
- ASA
- Lead sponsor
- Bayer
- Collaborator
- Janssen Scientific Affairs, LLC
Record details
- Record id
cardio:ct-nct02064439- Content hash
a86e14f27bee3ee120632b76bd72d5bdd110a9a6d7aba1d7dc534bf062875557